^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    GDF15-L

    i
    Other names: GDF15, MIC-1, MIC1, NAG-1, PDF, PLAB, PTGFB, Growth differentiation factor 15
    Entrez ID:
    9518
    Related biomarkers:
    Expression
    Others
    8ms
    Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. (PubMed, Prostate)
    Elevated circulating GDF15 is associated with poor prognosis in men with mCRPC receiving docetaxel and may be a marker of changes in the innate immune system in response to docetaxel resistance. These findings provide a strong rationale to consider GDF15 as a biomarker to guide a therapeutic trial of drugs targeting the innate immune system in combination with docetaxel in mCRPC.
    Journal • Metastases
    |
    IL6 (Interleukin 6) • GDF15 (Growth differentiation factor 15) • IL4 (Interleukin 4) • CD86 (CD86 Molecule)
    |
    GDF15-L • GDF15 elevation
    |
    docetaxel
    1year
    GDF15 IS A NOVEL PREDICTIVE MARKER FOR DEVELOPMENT OF NAFLD-ASSOCIATED LIVER CANCER (AASLD 2023)
    In NAFLD patients, high serum GDF15 is a risk factor for liver cancer development.
    GDF15 (Growth differentiation factor 15)
    |
    GDF15-L
    1year
    BIOMARKER-BASED IDENTIFICATION OF HIGH-RISK GROUPS FOR PRIMARY HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS UNDER THE NUCLEOS(T)IDE ANALOGUE TREATMENT (AASLD 2023)
    Stored sera were used to measure GDF15 using ELISA and HBcrAg using immunoassay for total antigen including complex by pretreatment (iTACT) technology... Male sex, high γ-GTP, high AFP, high GDF15 and fibrosis progression were high risk factors for the occurrence of primary HCC in CHB patients under NUC treatment.
    Clinical
    |
    GDF15 (Growth differentiation factor 15)
    |
    GDF15-L
    almost2years
    Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer. (PubMed, J Cancer Res Clin Oncol)
    Plasma GDF15 could be a potential biomarker for predicting the efficacy and survival benefit of immunotherapy in advanced NSCLC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • GDF15 (Growth differentiation factor 15) • CD4 (CD4 Molecule)
    |
    GDF15-L